세계의 CAR-T 세포치료 시장 규모는 2022년에 52억 달러로 평가되며, 2023년 72억 7,000만 달러에서 2031년에는 1,060억 6,000만 달러로 성장하며, 예측 기간(2024-2031년)에 39.80%의 CAGR로 성장할 전망입니다.
세계 암 유행은 향후 수년간 CAR-T 세포치료제 수요를 크게 견인할 것으로 예상됩니다. 세포 연구에 대한 투자 증가와 유전공학 기술의 발전으로 CAR-T 세포치료제 시장은 강력한 성장이 예상됩니다. 맞춤의료에 대한 관심이 높아지면서 특히 혈액암을 적응증으로 하는 CAR-T 세포치료에 대한 수요가 더욱 증가할 가능성이 높으며, 이는 이 분야 서비스 사업자들에게 새로운 비즈니스 기회를 제공할 것입니다. 또한 다양한 만성질환을 대상으로 한 혁신적인 CAR-T 세포치료제의 승인 빈도가 증가하고 있는 것도 세계 시장 확대 가능성을 지원하고 있습니다. 그러나 치료비 상승, 안전성 및 부작용 우려, 환자 접근성 제한 등 CAR-T 세포치료제의 잠재력을 극대화하고 더 많은 환자들에게 치료 기회를 제공하기 위해서는 이러한 장애요인을 해소하는 것이 중요합니다. 이러한 상황의 진전에 따라 시장 이해관계자들은 기술 발전과 암 분야의 미충족 의료 수요 증가에 따른 새로운 기회를 활용하면서 이러한 과제를 극복해 나가야할 것입니다.
Global CAR T-Cell Therapy Market size was valued at USD 5.2 billion in 2022 and is poised to grow from USD 7.27 billion in 2023 to USD 106.06 billion by 2031, growing at a CAGR of 39.80% during the forecast period (2024-2031).
The global cancer epidemic is anticipated to significantly drive the demand for CAR T-cell therapy in the upcoming years. With rising investments in cell research and advancements in genetic engineering technologies, the CAR T-cell therapy market is poised for robust growth. The increasing emphasis on personalized medicine is likely to further propel demand for CAR T-cell treatments, particularly in addressing blood cancer indications, which presents new opportunities for service providers in this field. Additionally, the growing frequency of approvals for innovative CAR T-cell therapies aimed at various chronic conditions underscores the expanding market potential on a global scale. However, the market faces challenges, including the high costs associated with treatment, concerns regarding procedural safety and potential side effects, as well as limited accessibility for patients. Addressing these restraints will be critical for unlocking the full potential of CAR T-cell therapies and ensuring they reach broader patient populations. As the landscape evolves, stakeholders in the CAR T-cell therapy market must navigate these challenges while capitalizing on emerging opportunities presented by technological advancements and increasing unmet medical needs in oncology.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Car T-Cell Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Car T-Cell Therapy Market Segmental Analysis
Global CAR T-Cell Therapy Market is segmented by Product, Target, Indication, Demographic, End User, and region. Based on Product, the market is segmented into Yescarta, Kymriah, Carvykti, Abecma, Tecartus, Breyanzi, and Other Products. Based on Target, the market is segmented into CD19, BCMA, and Other Targets. Based on Indication, the market is segmented into Multiple Myeloma, B-Cell Lymphoma, Acute Lymphoblastic Leukemia, and Other Indications. Based on Demographic, the market is segmented into Adults, and Pediatrics. Based on End User, the market is segmented into Hospitals, Specialty Centers, and Long-Term Care Facilities. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.
Driver of the Global Car T-Cell Therapy Market
The surge in personalized medicine is a significant market driver for the Global CAR T-Cell Therapy market, as it aligns closely with the growing demand for tailored healthcare solutions. As patients increasingly seek individualized treatment options, the ability of CAR T-cell therapy to be customized for each patient's unique tumor characteristics enhances its efficacy and appeal. This personalization not only improves therapeutic outcomes but also fosters patient engagement and adherence to treatment protocols. Consequently, the broader acceptance and integration of personalized medicine within oncology are expected to propel the CAR T-cell therapy market, leading to innovative advancements and expanding clinical applications in the coming years.
Restraints in the Global Car T-Cell Therapy Market
One significant market restraint for the Global CAR T-Cell Therapy market is the lingering uncertainty surrounding the long-term safety and potential side effects associated with this innovative treatment. Despite rigorous testing, concerns about adverse reactions, such as cytokine release syndrome and neurotoxicity, can lead to apprehension among patients and healthcare providers, ultimately hindering widespread adoption. Additionally, the complexity of administering CAR T-cell therapy and the requirement for specialized medical personnel and infrastructure further complicate its integration into standard cancer treatment protocols. This combination of safety concerns and logistical challenges may slow the growth of the CAR T-cell therapy market over the forecast period.
Market Trends of the Global Car T-Cell Therapy Market
The global CAR T-cell therapy market is witnessing a significant trend towards the development of allogeneic therapies, which utilize genetically modified T-cells derived from healthy donors rather than the patient's own cells. This innovation is driven by the potential for off-the-shelf treatment options that can provide quicker, more accessible solutions for patients with hematologic malignancies and solid tumors. With advancements in gene-editing technologies and the growing emphasis on reducing manufacturing complexities and costs, allogeneic CAR T-cell therapies are expected to gain traction, fostering increased investment and collaboration within the biopharmaceutical landscape. This shift promises to enhance patient outcomes while expanding market reach.